NASDAQ · DWTX
Dogwood Therapeutics, Inc.
$1.23-$0.01 (-0.81%)
Dogwood Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.54% below the high.
Loading market information…
NASDAQ · MBIO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Mustang Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.66% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Mustang Bio, Inc.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of -$140.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Mustang Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 |
|---|
| Nov 8, 2024 |
| -$2.00+69.23% vs estimate |
| $0.00 |
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.23-$0.01 (-0.81%)
Dogwood Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.54% below the high.
$1.01+$0.01 (+1.0%)
Marker Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.94% below the high.
$6.36-$0.22 (-3.34%)
Bolt Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.25% below the high.
$1.07$0.00 (0.0%)
Acurx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.81% below the high.
$0.92+$0.02 (+2.48%)
Immuron Limited’s quoted price sits in the lower half of its reported 52-week range, 56.69% below the high.
$0.30-$0.06 (-16.34%)
Traws Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.68% below the high.
$0.38+$0.01 (+1.6%)
Evogene Ltd.’s quoted price sits in the lower half of its reported 52-week range, 70.74% below the high.
$1.73-$0.01 (-0.57%)
TransCode Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.27% below the high.
